| Secondary outcomes |
---|---|
1. | Changes of ventilator efficiency (VE/VCO2 slope) |
2. | Ejection fraction |
3. | E velocity of mitral inflow, E′ velocity, systolic mitral annular velocity (S′ velocity) |
4. | E/E′ ratio |
5. | Deceleration time |
6. | Pulmonary artery systolic pressure measured by echocardiography at baseline and 12 weeks |
7. | Post-exercise pulmonary artery systolic pressure measured by echocardiography at baseline and 12 weeks |
8. | Symptomatic status (NYHA functional class and Borg dyspnea index) |
9. | Plasma concentration of BNP assessed at baseline, 4 weeks, and 12 weeks |
10. | Clinical endpoints, all-cause death, cardiac death, admission for heart failure, and the composites of these events will be assessed until the end of the study period |
11. | Development of facial flushing, febrile sensation, eyeball pain, visual disturbance, headache, penile erection, intolerance or development of other adverse drug reactions related with study drug will be assessed |